SEC Form 4 · accession 0001179110-17-012310
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Sep 12, 2017
Accepted (ET)
Sep 14, 2017 · 8:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Sep 12, 2017 | S | 10,458 | $8.6284 | D | 2,360,278 | D | |
| Ordinary SharesF3 | Sep 13, 2017 | S | 22,721 | $8.5364 | D | 2,337,557 | D | |
| Ordinary SharesF4 | Sep 14, 2017 | S | 3,429 | $8.5225 | D | 2,334,128 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.53 to $8.825. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.
- F2The balance was adjusted by one (1) share to account for a mathematical error in a prior filing.
- F3The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.685. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price
- F4The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.6386. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.